BioSpace News Archive

BioSpace spoke with three CEOs: Alto Neuroscience’s Dr. Amit Etkin, Omega Therapeutics’ Mahesh Karande and Rain Therapeutics’ Avanish Vellanki about their companies’ employment growth.

Ascletis Pharma Inc. announces the latest Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 in patients with chronic hepatitis B at an oral parallel session of the International Liver Congress™ 2022 held by the European Association for the Study of the Liver.

Innovent Biologics, Inc. and Eli Lilly and Company, announced that the National Medical Products Administration of China has approved the supplemental New Drug Application for TYVYT® in combination with fluorouracil and platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.

Antengene Corporation Limited announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene’s anti-PD-1 checkpoint inhibitor, tislelizumab.

Astellas Pharma Inc. announced that the US Food and Drug Administration has placed a clinical hold on the FORTIS Phase 1/2 trial following the occurrence of a serious adverse event of peripheral sensory neuropathy in one of the trial participants.